
Eisai Presents Real-World Lecanemab Data at AD/PD 2025 Confirming Phase 3 Clinical Trial Findings
Real-world clinical evidence presented at the 2025 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) demonstrates that lecanemab use in clinical practice aligns with FDA-approved prescribing recommendations, with patient …